Search on Site

Explore our comprehensive database of pharmaceutical news releases, press releases, events, and industry insights with ease. Effortlessly find relevant information tailored to your interests and stay updated on the latest developments in the pharmaceutical sector. Start searching now to uncover valuable insights and resources for your pharmaceutical endeavors.

Space Cargo Unlimited and Exobiosphere Partner for High-Throughput Space Biotech

will be carried first aboard Phoenix—a re-entry capable, small-scale free-flyer developed by ATMOS-, and ultimately REV1, full-scale free flyer developed by Space Cargo Unlimited to enable frequent and cost-effective research in space. "Space Cargo...

Boehringer Ingelheim and the Lung Cancer Research Foundation Announce New Research Collaboration

Investigator Award. Lung cancer is responsible for more deaths worldwide than any other cancer, accounting for an estimated 130,180 deaths annually in the United States alone.1 In the last 10 to 15 years, accelerated clinical trials and FDA...

Dupixent® outperformed Xolair® in treating CRSwNP with asthma in the first Phase 4 head-to-head trial

trial, 360 adults with severe, uncontrolled CRSwNP and coexisting asthma were randomized to receive Dupixent 300 mg (n=181) every two weeks or a weight- and immunoglobulin E (IgE) level-based dosing regimen of Xolair (n=179) every two or four...

To Target the Multi-Billion Dollar Kidney Disease Market, Mezzion Expands Its Udenafil Pipeline to ADPKD

Dr. Fouad Chebib. ADPKD, a prevalent genetic disorder characterized by the growth of numerous kidney cysts, affects about 1 in 400 to 1,000 people worldwide. The disease progressively impairs kidney function, often leading to kidney failure....

Ratio Therapeutics partners with Macrocyclics for exclusive production and global distribution of its Macropa™ radiopharmaceutical platform

aligned in the mission to improve patient outcomes through targeted cancer therapies and diagnostics." Incorporated in 1995, Macrocyclics is a CDMO specialized in chelating agents for radiopharmaceuticals and nuclear medicine. The company maintains...

Samsung Biologics introduces 'Samsung Organoids'—a novel drug screening service utilizing lab-grown human organ models to enhance oncology research

Samsung Biologics a leading contract development and manufacturing organization (CDMO), today announced the launch of Samsung Organoids – advanced drug screening services to support clients in drug discovery and development. Organoids are...

Genmab: Epcoritamab combo shows high response in R/R DLBCL patients eligible for ASCT

Genmab A/S announced new results from the Phase 1b/2 EPCORE® NHL-2 trial Arm 10 (NCT04663347), evaluating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, in combination with rituximab, ifosfamide, carboplatin, and...

The iPSCore™ platform, developed by iXCells Biotechnologies, enables the generation of highly characterized iPSC-derived human cell models

which can be used in an assortment of downstream assays tailored to customer needs. Currently the platform processes >1,000 samples per year with routinely >96% success rate and is expected to multiply the output of patient-derived iPSC-derived...

Nuvation Bio’s IBTROZI™ (taletrectinib), a next-generation oral treatment for advanced ROS1-positive non-small cell lung cancer, has been approved by the U.S. Food and Drug Administration

(FDA) has approved IBTROZI™ (taletrectinib) for the treatment of adult patients with locally advanced or metastatic ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC). IBTROZI is a highly selective, next-generation oral ROS1 tyrosine kinase...

Avanzanite forms a Pan-European partnership with Agios to introduce PYRUKYND® for rare blood disorders

also includes potential future indications. Avanzanite is rapidly scaling its operations, having tripled its revenue in Q1 2025 year-over-year, with two rare disease medicines already on the market. Over the next 12 months, the company will expand...

Lubrizol reveals a significant milestone for its innovative, patented Apisolex™ polymer excipient

Lubrizol announces that an Apisolex™ polymer excipient-enabled drug formulation is in Phase 1 clinical trials. Introduced to the market in 2022, Apisolex polymer excipient is a polyamino acid-based polymer that enhances the solubility of BCS Class...

CollPlant expands its partnership with Stemcell Technologies.

These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. In 2021, CollPlant entered into a development and global commercialization agreement for dermal and soft tissue fillers with Allergan,...

Emulate introduces the AVA™ Emulation System, a groundbreaking high-throughput organ-chip platform designed to accelerate drug development

half, thanks to automated microscopy, remote monitoring, and the revolutionary new Chip-Array™ consumable that integrates 12 independent Organ-Chips into an SBS format for streamlined workflows with multichannel pipettes and automated liquid...

A New Production Line Dedicated to Sterile Hyaluronic Acid Has Been Inaugurated by HTL Biotechnology

bringing improved clinical benefits for patients in many fields, such as ophthalmology and drug delivery. This €12 million investment, part of HTL Biotechnology's €100 million 2022-2026 strategic plan, pursues two main goals: to explore new...

Vertex Shares New Data on ALYFTREK® Benefits and Sweat Chloride Reduction

Vertex Pharmaceuticals Incorporated announced data across multiple studies demonstrating positive clinical and quality of life benefits of treatment with CFTR modulators and, in particular, ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor), which...

Elysium Therapeutics to Discuss Fentanyl Rebound and Synthetic Opioid Rescue Drug

delivered via long-acting injection (LAI) technology. The technology is designed to rapidly restore respiration and provide 18 – 24 hours of effective opioid blockade to minimize the risk of re-narcotization, while also providing protection from...

CollPlant Biotechnologies Announces First Quarter 2025 Financial Results and Issues Corporate Update

These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. In 2021, CollPlant entered into a development and global commercialization agreement for dermal and soft tissue fillers with Allergan,...

Samsung Bioepis and Organon’s HADLIMA™ Gains FDA Interchangeability Designation, Expanding Access to Adalimumab Alternative

designation received for the HADLIMA low-concentration (40 mg/0.8 mL) prefilled syringe and single-dose vial in June 2024.1 With today’s additional interchangeability designations, HADLIMA is now interchangeable with all presentations of the...

Avenacy Enters U.S. Market with Launch of Doxycycline for Injection, USP

announced it has launched Doxycycline for Injection, USP in the United States as a therapeutic generic equivalent for DOXY 100®, as approved by the U.S. Food and Drug Administration. Doxycycline for Injection, USP is a broad-spectrum antibiotic...

Fresenius Kabi Introduces Epinephrine Injection, USP, in 30 mg/30 mL Multi-Dose Vials

Epinephrine Injection 30 mg per 30 mL is a prescription medicine used for emergency treatment of allergic reactions (Type 1), including anaphylaxis, in adults and pediatric patients and to increase mean arterial blood pressure in adult patients...